![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631638143617-8C6MG465PVBU2FQYEVXO/emperor-preserved+primary.png?format=1000w)
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
![β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. | Semantic Scholar β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/638123a949ed9ed7abdeffb6db75599f34dd935f/2-Table1-1.png)
β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. | Semantic Scholar
![Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie, - ppt download Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie, - ppt download](https://images.slideplayer.com/22/6366646/slides/slide_6.jpg)
Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie, - ppt download
![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631642603427-LHGX5Z37VKPX9PGU0NLV/emperor-preserved+efficacy.png?format=1000w)
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
![I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Peter Carson and Barry Massie Executive Committee M. Komajda, R. McKelvie, J. McMurray, - ppt download I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Peter Carson and Barry Massie Executive Committee M. Komajda, R. McKelvie, J. McMurray, - ppt download](https://images.slideplayer.com/8/2372555/slides/slide_20.jpg)
I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Peter Carson and Barry Massie Executive Committee M. Komajda, R. McKelvie, J. McMurray, - ppt download
![Abstract 16784: Under-Enrollment of Real-World Heart Failure With Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials | Circulation Abstract 16784: Under-Enrollment of Real-World Heart Failure With Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials | Circulation](https://www.ahajournals.org/cms/asset/2e097f4d-03d4-4438-a5b7-c82d9ab27d49/g16784.jpg)
Abstract 16784: Under-Enrollment of Real-World Heart Failure With Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials | Circulation
![Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine – the PRESERVE Trial | Cardiology Now Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine – the PRESERVE Trial | Cardiology Now](http://cardiologynownews.org/wp-content/uploads/2018/04/PRESERVE-trial.jpg)
Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine – the PRESERVE Trial | Cardiology Now
![Diagram of the stepwise evaluation of endpoints in the EMPEROR-Reduced... | Download Scientific Diagram Diagram of the stepwise evaluation of endpoints in the EMPEROR-Reduced... | Download Scientific Diagram](https://www.researchgate.net/publication/346492631/figure/fig1/AS:998409959927814@1615050892770/Diagram-of-the-stepwise-evaluation-of-endpoints-in-the-EMPEROR-Reduced-and.png)
Diagram of the stepwise evaluation of endpoints in the EMPEROR-Reduced... | Download Scientific Diagram
![PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356 PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356](https://image.slideserve.com/224356/i-preserve-trial-irbesartan-in-heart-failure-with-preserved-ef-l.jpg)
PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356
![The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction) | JACC: Heart Failure The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction) | JACC: Heart Failure](https://www.jacc.org/cms/asset/b2472838-5ed8-46f0-805a-57d05882c110/gr1.jpg)
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction) | JACC: Heart Failure
![Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177921005837-fx1.jpg)
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
![PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease | Stroke PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease | Stroke](https://www.ahajournals.org/cms/asset/bc3dfd3e-fe2f-4f09-8911-cd841f7fd33b/strokeaha.120.032054.fig04.jpg)
PRESERVE: Randomized Trial of Intensive Versus Standard Blood Pressure Control in Small Vessel Disease | Stroke
![The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction – Visualmed The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction – Visualmed](https://www.visualmed.org/wp-content/uploads/2023/04/CHARM-preserved.jpg)
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction – Visualmed
![Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke](https://www.usherbrooke.ca/baladocritique/fileadmin/sites/baladocritique/documents/Infographie_Emperor-Preserved.png)
Épisode 43: ÉTUDE EMPEROR-Preserved - BaladoCritique : Club de lecture médical - Université de Sherbrooke
![PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356 PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356](https://image.slideserve.com/224356/slide9-l.jpg)
PPT - I-PRESERVE Trial Irbesartan in heart failure with preserved EF PowerPoint Presentation - ID:224356
![Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Elsevier e-Prints Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Elsevier e-Prints](http://ereprints.elsevier.es/system/files/articles/assets/S2213177917303190/1141/fx1.jpg)
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Elsevier e-Prints
![PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3092ad4f375a1465b7d1d3a99b6ec0e96ba95eef/5-Figure1-1.png)
PDF] What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? | Semantic Scholar
![Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial - Anker - 2020 - European Journal of Heart Failure - Wiley Online Library Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial - Anker - 2020 - European Journal of Heart Failure - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/56b76de6-7350-4813-a20b-64c67caa7c78/ejhf2064-fig-0001-m.jpg)